Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Boehringer Ingelheim to expand Pradaxa production capabilities

Boehringer Ingelheim to expand Pradaxa production capabilities

16th April 2010

Boehringer Ingelheim is to expand one of its production sites in Ingelheim, Germany in order to meet rising global demand for its anticoagulant Pradaxa.

The pharmaceutical company held a topping-out ceremony to mark the progress of construction work at the plant, which is set to be completed in 2011.

Once work on the site is finished, the company will be able to triple production of the dabigatran etexilate-based drug, which is approved in Europe for preventing thrombosis and pulmonary embolisms among hip or knee replacement surgery patients.

The firm states that this expansion has been made necessary to meet an expected increase in global demand for the drug, which it is now trialling as a potential treatment for atrial fibrillation.

Professor Wolfram Carius, member of the board of managing directors at Boehringer Ingelheim, added: “This is not just about increased capacity for production of a highly innovative new medicine. The plant’s construction is also a reflection of our company’s innovative capacity.”

This comes after the company last month published a clinical study comparing dabigatran etexilate to warfarin in treating atrial fibrillation, showing its effectiveness in reducing stroke occurrences.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.